Some news that flew under the radar at the end of last month, except if you live in the Midlands, was that preventative healthcare technology company Neko Health has brought its ‘revolutionary' body scanner to Birmingham to help people stay steps ahead of any potential health issues.

The Stockholm-based company, which is owned by Spotify founder Daniel Ek, has opened its fifth global health centre in the city after launching in London, Manchester, and Sweden.

Neko Health's offering, which combines its full-body scan and a consultation with one of the company's medical professionals over 60 minutes, offers a glimpse of what healthcare could look like in the future.

The Neko Body Scan uses the latest advances in sensors and AI to aid early detection, and looks a bit like something out of Star Trek.

The comprehensive, non-invasive and radiation-free health assessment captures millions of health data points. Using proprietary sensors alongside blood analysis, the scan assesses skin health, including moles and marks, blood sugar levels to identify pre-diabetes risk, blood abnormalities, and risk factors linked to metabolic syndrome, stroke and heart attack. 

Results are delivered on-site within minutes and members provided with personalised and actionable health findings. 

The scan, which apparently takes 20 seconds for front and back, is currently priced at £299.

The Birmingham site, which is registered with the CQC, is conveniently located in Livery Street. The location was selected to be easily accessible for people across the city and surrounding areas. At full capacity, it will be able to deliver up to 25,000 scans per year.

The business, which sees nearly 80% of members choose to rebook and prepay for their next scan the following year, has already attracted a loyal following.

As global medical director at Neko Health, Dr Nikita Kanani, explains: ‘In clinical practice, we see the consequences of late diagnosis every day. The ability to assess metabolic, cardiovascular, and dermatological risks in a single, non-invasive visit represents an important step forward in preventive healthcare.'

The company's grand scheme seems to be working, with data from returning members showing measurable improvements in blood pressure, cholesterol, and blood sugar. 

The strongest improvements came from members with hypertension, prediabetes, or diabetes. These groups showed consistent decreases in blood pressure, cholesterol, and blood sugar between their first and second scans.

The results offer early evidence that proactive tracking and personalised feedback can help people make meaningful changes to their health. So it should come as no surprise that Neko Health continues to see strong global demand, delivering six times more scans in 2025 than a year earlier, with global signups now exceeding 300,000 people. And the company's growth is set to continue in the spring with a health centre in New York.